151 related articles for article (PubMed ID: 6262143)
41. Development of pertussis serological potency test. Serological assessment of antibody response induced by whole cell vaccine as an alternative to mouse protection in an intracerebral challenge model.
van der Ark A; van Straaten-van de Kappelle I; Akkermans A; Hendriksen C; van de Donk H
Biologicals; 1994 Sep; 22(3):233-42. PubMed ID: 7811457
[TBL] [Abstract][Full Text] [Related]
42. Trypsin diminishes the rat potency of polio serotype 3.
ten Have R; Westdijk J; Levels LM; Koedam P; de Haan A; Hamzink MR; Metz B; Kersten GF
Biologicals; 2015 Nov; 43(6):474-8. PubMed ID: 26321654
[TBL] [Abstract][Full Text] [Related]
43. Enzyme-linked immunosorbent assay assessment of bovine viral diarrhea virus antigen in inactivated vaccines using polyclonal or monoclonal antibodies.
Ludemann LR; Katz JB
Biologicals; 1994 Mar; 22(1):21-7. PubMed ID: 8068310
[TBL] [Abstract][Full Text] [Related]
44. [Antibody production against poliovirus N and H antigens by immunization of guinea pigs].
Mietens C; Fuhrmeister U
Arch Gesamte Virusforsch; 1971; 34(1):23-31. PubMed ID: 4329437
[No Abstract] [Full Text] [Related]
45. [The influence of the first antigenic stimulus upon further immunizability. Guinea pig experiments with poliomyelitis virus vaccines].
Sandow J
Zentralbl Bakteriol Orig; 1969; 209(3):389-406. PubMed ID: 5379832
[No Abstract] [Full Text] [Related]
46. Vaccines based on recombinant antigen strategies.
Minor P
Dev Biol (Basel); 2001; 105():189-94. PubMed ID: 11763327
[No Abstract] [Full Text] [Related]
47. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study.
Halperin SA; McDonald J; Samson L; Danzig L; Santos G; Izu A; Smith B; MacDonald N
Clin Invest Med; 2002 Dec; 25(6):243-51. PubMed ID: 12516995
[TBL] [Abstract][Full Text] [Related]
48. Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd.
Von Seefried A; Chun JH; Grant JA; Letvenuk L; Pearson EW
Rev Infect Dis; 1984; 6 Suppl 2(Suppl 2):S345-9. PubMed ID: 6330837
[TBL] [Abstract][Full Text] [Related]
49. Rat immunogenicity assay of inactivated poliovirus.
Bevilacqua JM; Young L; Chiu SW; Sparkes JD; Kreeftenberg JG
Dev Biol Stand; 1996; 86():121-7. PubMed ID: 8785941
[TBL] [Abstract][Full Text] [Related]
50. Use of in vitro Vero cell assay and ELISA in the United States potency test of vaccines containing adsorbed diphtheria and tetanus toxoids.
Gupta RK; Siber GR
Dev Biol Stand; 1996; 86():207-15. PubMed ID: 8785950
[TBL] [Abstract][Full Text] [Related]
51. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus.
Herremans TM; Reimerink JH; Buisman AM; Kimman TG; Koopmans MP
J Immunol; 1999 Apr; 162(8):5011-8. PubMed ID: 10202050
[TBL] [Abstract][Full Text] [Related]
52. [Properties of poliovirus detected in waste waters in the administration of nonhomogeneous vaccine (author's transl)].
Matyásová I; Koza J
Cesk Epidemiol Mikrobiol Imunol; 1981 Jan; 30(1):49-55. PubMed ID: 6258812
[No Abstract] [Full Text] [Related]
53. The potential of retro-inverso peptides as synthetic vaccines.
Van Regenmortel MH; Guichard G; Benkirane N; Briand JP; Muller S; Brown F
Dev Biol Stand; 1998; 92():139-43. PubMed ID: 9554267
[TBL] [Abstract][Full Text] [Related]
54. Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose regimen.
Salk J; Stoeckel P; van Wezel AL; Lapinleimu K; van Steenis G
Ann Clin Res; 1982 Dec; 14(5-6):204-12. PubMed ID: 7171229
[TBL] [Abstract][Full Text] [Related]
55. Swedish inactivated polio vaccine: laboratory standardization and clinical experience over a 30-year period.
Böttiger M; Larsson B
Biologicals; 1992 Dec; 20(4):267-75. PubMed ID: 1305403
[TBL] [Abstract][Full Text] [Related]
56. A solid phase radioimmunoassay for poliovirus D-antigen.
Talbot P
Dev Biol Stand; 1981; 47():87-90. PubMed ID: 6262164
[TBL] [Abstract][Full Text] [Related]
57. [Experiments with depot vaccines].
Henneberg G
Arzneimittelforschung; 1965 Sep; 15(9):1003-8. PubMed ID: 4955784
[No Abstract] [Full Text] [Related]
58. Inactivated vaccines based on alternatives to wild-type seed virus.
Chumakov K; Dragunsky E; Ivshina A; Enterline J; Wells V; Nomura T; Gromeier M; Wimmer E
Dev Biol (Basel); 2001; 105():171-7. PubMed ID: 11763325
[No Abstract] [Full Text] [Related]
59. Parameters for differentiating vaccine-derived and wild poliovirus strains.
Nakano JH; Hatch MH; Thieme ML; Nottay B
Prog Med Virol; 1978; 24():178-206. PubMed ID: 212784
[No Abstract] [Full Text] [Related]
60. A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture.
Nagarajan T; Reddy GS; Mohana Subramanian B; Rajalakshmi S; Thiagarajan D; Tordo N; Jallet C; Srinivasan VA
Biologicals; 2006 Mar; 34(1):21-7. PubMed ID: 16188454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
